Study Links Alternative Funding Programs to Treatment Delays as Black Market for Investigational Weight-Loss Drugs Surges
Key Insights
New research shows patients in alternative funding programs (AFPs) face significantly greater barriers to accessing specialty medications, with nearly one in five turning to overseas pharmacies.
Drug manufacturers are increasingly denying patient assistance applications linked to AFPs, leading to longer treatment delays, therapy interruptions, and poorer clinical outcomes.
FDA import data from March–April 2026 reveals unapproved investigational obesity (search) drugs, including Eli Lilly's retatrutide, entering the U.S. from unregistered manufacturers under generic customs codes.
New research has found that patients enrolled in alternative funding programs (AFPs) face significantly greater barriers to accessing specialty medications compared with other commercially insured patients, according to findings published by the Partnership for Safe Medicines. The study revealed that drug manufacturers are increasingly denying patient assistance applications linked to AFPs, resulting in longer treatment delays, more therapy interruptions, and poorer clinical outcomes.
The research also documented that nearly one in five AFP patients ultimately obtained medications through overseas pharmacies, raising serious concerns about product quality, supply chain integrity, and exposure to counterfeit medicines. Health-system specialty pharmacies reported greater administrative burdens associated with managing AFP-linked cases.
Black Market for Investigational Weight-Loss Drugs Accelerates
A parallel investigation highlights the growing black market for retatrutide, Eli Lilly's experimental obesity (search) and diabetes (search) treatment that has not yet been submitted for FDA approval. A New York Times investigation cited PSM research showing that approximately 15 pounds of retatrutide entered the United States between January and April 2026, with consumers obtaining the product through online sellers, social media networks, and overseas suppliers.
"The only safe way to consume retatrutide is through an Eli Lilly clinical trial. All other sellers of the compound are black market, illegal sellers," the Partnership for Safe Medicines stated in its analysis.
Australian health officials and physicians have issued urgent warnings about counterfeit products marketed as retatrutide, following multiple cases of severe illness including acute liver failure (search), kidney injury (search), and hospitalizations. These products were purchased through social media, beauty clinics, and online sources. Experts emphasized that any product sold as retatrutide is an unregulated black-market product of unknown composition posing significant patient safety risks.
FDA Import Enforcement Shows Early Impact
In September 2025, the FDA launched an import enforcement framework targeting foreign-sourced weight loss active pharmaceutical ingredients used in compounding. Under the policy, foreign semaglutide and tirzepatide API shipments could be detained without physical examination unless they came from manufacturers the FDA had reviewed and added to the agency's "green list."
Data from March and April 2026 suggest that increased FDA scrutiny is altering the behavior of illicit importers. By making the raw API channel hostile to unvetted labs, the FDA has successfully squeezed bad actors, forcing them to resort to alternate customs declarations to evade detection.
One of the clearest trends in the March–April 2026 data was the appearance of unapproved, investigational obesity (search) and diabetes (search) drugs entering the country under the generic "antidiabetics n.e.c (not elsewhere classified)" product code. The most significant example was retatrutide, with six shipments flagged from unregistered manufacturers, most of which were released into the United States. Five released shipments were investigational API shipments from Changzhou Sta Life Science Co Limited in China, while one refused shipment came from an Australian compounding pharmacy.
Global Counterfeit Medicine Concerns Mount
The counterfeit medicine threat extends beyond weight-loss drugs. Authorities in Tajikistan dismantled an alleged counterfeit medicine operation that produced and distributed fake versions of popular pediatric and over-the-counter drugs, including Nurofen and Paracetamol. Police seized tens of thousands of bottles and large quantities of packaging materials and raw ingredients, warning that products manufactured in unsanitary conditions without proper licensing posed a significant risk to public health.
In Nigeria, officials warned that counterfeit Augmentin 625mg tablets are circulating, with fake products closely resembling genuine GSK-manufactured Augmentin, including the use of the same batch number "AC3N."
The UK's Medicines and Healthcare products Regulatory Agency (MHRA), Advertising Standards Authority (ASA), and General Pharmaceutical Council (GPhC) issued a joint warning that businesses should not advertise unlicensed weight-loss medicines or prescription-only GLP-1 products to the public, including through waiting lists or promotional references to upcoming products.
Regulatory Actions on Manufacturing Quality
The FDA issued a warning letter to a Greece-based manufacturer of sterile injectable drugs, citing concerns about product sterility, contamination risks, inadequate investigations, and data integrity failures. Inspectors identified deficiencies in aseptic processing, environmental controls, laboratory documentation, and quality oversight, leading the company to suspend U.S. production and support voluntary recalls of certain injectable products.
Additionally, the FDA issued a warning letter to a Canadian manufacturer of over-the-counter drug products, citing violations including inadequate testing of high-risk raw materials, insufficient process validation, and weak oversight of the quality system.
Emerging Regulatory Challenges
The emergence of investigational compounds like retatrutide on the black market presents a difficult challenge for regulators. Unlike semaglutide and tirzepatide, where the FDA has spent years responding to shortages, compounding, and illicit imports, many newer drugs are still investigational. Public awareness, online demand, and black market sourcing are accelerating faster than existing enforcement systems were designed to handle.